DBV Technologies (NASDAQ:DBVT) Stock Price Up 7.2% – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT) shares rose 7.2% during trading on Friday . The company traded as high as $17.00 and last traded at $17.20. Approximately 6,160 shares traded hands during trading, a decline of 98% from the average daily volume of 289,443 shares. The stock had previously closed at $16.04.

Wall Street Analysts Forecast Growth

DBVT has been the topic of a number of analyst reports. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Monday, May 4th. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Finally, Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Stock Up 5.3%

The company has a market cap of $1.03 billion, a P/E ratio of -3.91 and a beta of -0.99. The firm has a 50 day moving average of $19.42 and a 200-day moving average of $19.64.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. On average, research analysts predict that DBV Technologies S.A. will post -0.47 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

A number of hedge funds have recently bought and sold shares of the stock. Artisan Partners Limited Partnership lifted its holdings in DBV Technologies by 6,273.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after buying an additional 3,257,135 shares during the period. Vivo Capital LLC lifted its holdings in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after buying an additional 205,943 shares during the period. Siren L.L.C. purchased a new stake in DBV Technologies during the fourth quarter worth $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies during the second quarter worth $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in DBV Technologies during the second quarter worth $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.